

July 04, 2021

The Manager, Listing Department
The National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol : PANACEABIO

BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001
BSE Scrip Code: 531349

Re.: Press Release - Receipt of manufacturing license to produce Sputnik V vaccine at Baddi, Himachal Pradesh

Dear Sir/Madam,

The Company is delighted to announce the receipt of manufacturing license from Drug Controller General (India) for Sputnik V vaccine against Covid-19 pursuant to its collaboration with Russian Direct Investment Fund (Russia's sovereign wealth fund).

Sputnik V was registered in India under the emergency use authorization procedure on April 12, 2021 and vaccination against Covid-19 with the Russian vaccine started on May 14, 2021.

Sputnik V has been registered in 67 countries globally with total population of over 3.5 billion people.


A copy of the Press Release titled “**Panacea Biotec announces receipt of manufacturing license to produce Sputnik V vaccine at Baddi, Himachal Pradesh**” being issued to the media, etc. in this regard is enclosed for your kind reference and record please.

Kindly acknowledge the receipt.

Thanking you,

Sincerely yours,

for **Panacea Biotec Ltd.**



Vinod Goel
Group CFO and Head Legal
& Company Secretary

Encl. As Above

Panacea Biotec announces receipt of manufacturing license to produce Sputnik V vaccine at Baddi, Himachal Pradesh

New Delhi, July 04, 2021 – Panacea Biotec, one of the leading vaccine and pharmaceutical producers in India, announces receipt of manufacturing license from Drugs Controller General (India) for Sputnik V vaccine against Covid-19 pursuant to its collaboration with Russian Direct Investment Fund (Russia’s sovereign wealth fund). The license is a necessary condition for using Sputnik V produced by Panacea Biotec in India.

The batches produced at Panacea Biotec’s facilities at Baddi, Himachal Pradesh were earlier shipped to the Gamaleya Center in Russia for quality control. The said batches have successfully passed all the checks for quality parameters both at the Gamaleya Center in Russia and at the Central Drug Laboratory, Kasauli, Himachal Pradesh in India.

Sputnik V was registered in India under the emergency use authorization procedure on April 12, 2021 and vaccination against Covid-19 with the Russian vaccine started on May 14, 2021.

Sputnik V has been registered in 67 countries globally with total population of over 3.5 billion people.

The vaccine is based on a proven and well-studied platform of human adenoviral vectors and uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots.


Dr. Rajesh Jain, Managing Director, for Panacea Biotec, said:

“Panacea Biotec is delighted to announce the obtaining of the manufacturing license to produce Sputnik V vaccine in India. At this occasion, we thank the leadership of our Hon’ble Prime Minister Modi ji and Government of India for timely handholding and expediting clearances to enable ‘Make in India’ vaccines.”

Sputnik V has a number of key advantages:

- *The Sputnik V vaccine is based on a proven and well-studied platform of human adenoviral vectors, which cause the common cold and have been around for thousands of years.*
- *Sputnik V uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots.*
- *The safety, efficacy and lack of negative long-term effects of adenoviral vaccines have been proven by more than 250 clinical studies over two decades.*
- *There are no strong allergies caused by Sputnik V.*
- *The storage temperature of Sputnik V at +2+8 C means it can be stored in a conventional refrigerator without any need to invest in additional cold-chain infrastructure.*

The price of Sputnik V is less than \$10 per shot, making it affordable around the world.




Panacea Biotec Ltd (CIN: L33117PB1984PLC022350)

Regd. Office : Ambala Chandigarh Highway, Lalru – 140501, Punjab

Correspondence/Corporate office : B-1 Extn./G-3, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi - 110 044, India

Ph.: 91-11-4167 9000, 4167 8000, Fax: 91-11-4167 9070 Email: companysec@panaceabiotec.com



Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF's management company is based in Moscow. Currently, RDIF has experience of the successful joint implementation of more than 80 projects with foreign partners totaling RUB 2.1 tn and covering 95% of the regions of the Russian Federation. RDIF portfolio companies employ more than 800,000 people and generate revenues which equate to more than 6% of Russia's GDP. RDIF has established joint strategic partnerships with leading international co-investors from more than 18 countries that total more than \$40 bn. Further information can be found at www.rdif.ru

Panacea Biotec is an innovation-led biopharmaceutical group that focuses on discovery, development, and commercialisation of prescription medicines primarily, focusing on Vaccines, Diabetes, Transplant, Gastroenterology, and Oncology. Panacea Biotec launched the world's first fully-liquid Hexavalent vaccine (DTwP-Hib-HepB-IPV), EasySix in 2017. Company is also developing a Dengue Vaccine, Pneumococcal Conjugate vaccine among other differentiated drug development programs. Panacea Biotec remains focused on merging cutting-edge science and technology with an unwavering commitment towards unmet medical needs while ensuring affordability. For more information, visit: www.panaceabiotec.com

Panacea Biotec: For Investors

Mr. Devender Gupta

Chief Financial Officer and Head Information Technology

Tel: + 91-11-41679000 Ext. 1225, 41578011
(Direct)

Mobile: + 91 98109 04102,

Email: devendergupta@panaceabiotec.com

Panacea Biotec: For Media

Mr. P. D. Karan

Vice President - Corporate Communication & Business Development

Tel: + 91 11 41679000 Extn. 1406,
41578080 (Direct)

Mobile: + 91 9312693040,
+ 91 9810500539

Email: pdkaran@panaceabiotec.com

